{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:07:38Z","timestamp":1791248858353,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T00:00:00Z","timestamp":1301875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1741-7015-9-32","type":"journal-article","created":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T19:41:44Z","timestamp":1302118904000},"source":"Crossref","is-referenced-by-count":197,"title":["Recent advances in the treatment of Pseudomonas aeruginosainfections in cystic fibrosis"],"prefix":"10.1186","volume":"9","author":[{"given":"Niels","family":"H\u00f8iby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,4]]},"reference":[{"key":"382_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1183\/09031936.03.00057003","volume":"23","author":"RC Boucher","year":"2004","unstructured":"Boucher RC: New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J. 2004, 23: 146-158. 10.1183\/09031936.03.00057003.","journal-title":"Eur Respir J"},{"key":"382_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1286-4579(00)01349-6","volume":"3","author":"N H\u00f8iby","year":"2001","unstructured":"H\u00f8iby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A: Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001, 3: 23-35.","journal-title":"Microbes Infect"},{"key":"382_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1136\/bmj.310.6994.1571","volume":"310","author":"DS Armstrong","year":"1995","unstructured":"Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD: Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ. 1995, 310: 1571-1572.","journal-title":"BMJ"},{"key":"382_CR4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/ppul.20294","volume":"40","author":"DS Armstrong","year":"2005","unstructured":"Armstrong DS, Hook SM, Jamsen KM, Nixon GM, Carzino R, Carlin JB, Robertson CF, Grimwood K: Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005, 40: 500-510. 10.1002\/ppul.20294.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR5","first-page":"66","volume":"35","author":"N H\u00f8iby","year":"2006","unstructured":"H\u00f8iby N, Pressler T: Emerging pathogens in cystic fibrosis. Eur Respir Mon. 2006, 35: 66-78.","journal-title":"Eur Respir Mon"},{"key":"382_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jcf.2008.06.009","volume":"7","author":"CR Hansen","year":"2008","unstructured":"Hansen CR, Pressler T, H\u00f8iby N: Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros. 2008, 7: 523-530. 10.1016\/j.jcf.2008.06.009.","journal-title":"J Cyst Fibros"},{"key":"382_CR7","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1128\/IAI.73.4.2504-2514.2005","volume":"73","author":"N Hoffmann","year":"2005","unstructured":"Hoffmann N, Rasmussen TB, Jensen P\u00d8, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK, H\u00f8iby N: Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun. 2005, 73: 2504-2514. 10.1128\/IAI.73.4.2504-2514.2005.","journal-title":"Infect Immun"},{"key":"382_CR8","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1128\/IAI.01282-06","volume":"75","author":"L Jelsbak","year":"2007","unstructured":"Jelsbak L, Johansen HK, Frost AL, Th\u00f8gersen R, Thomsen LE, Ciofu O, Yang L, Haagensen JA, H\u00f8iby N, Molin S: Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect Immun. 2007, 75: 2214-2224. 10.1128\/IAI.01282-06.","journal-title":"Infect Immun"},{"key":"382_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ppul.21011","volume":"44","author":"T Bjarnsholt","year":"2009","unstructured":"Bjarnsholt T, Jensen P\u00d8, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, H\u00f8iby N: Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009, 44: 547-558. 10.1002\/ppul.21011.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR10","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2217\/fmb.10.125","volume":"5","author":"N H\u00f8iby","year":"2010","unstructured":"H\u00f8iby N, Ciofu O, Bjarnsholt T: Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 2010, 5: 1663-1674.","journal-title":"Future Microbiol"},{"key":"382_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jcf.2009.10.005","volume":"9","author":"CR Hansen","year":"2010","unstructured":"Hansen CR, Pressler T, Nielsen KG, Jensen P\u00d8, Bjarnsholt T, H\u00f8iby N: Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros. 2010, 9: 51-58. 10.1016\/j.jcf.2009.10.005.","journal-title":"J Cyst Fibros"},{"key":"382_CR12","volume-title":"Pulmonary Physiology and Pathophysiology","author":"JB West","year":"2001","unstructured":"West JB: Pulmonary Physiology and Pathophysiology. 2001, Philadelphia: Lippincott Williams & Wilkins"},{"key":"382_CR13","first-page":"571","volume":"1","author":"N H\u00f8iby","year":"2006","unstructured":"H\u00f8iby N: P. aeruginosa in cystic fibrosis patients resists host defenses, antibiotics. Microbe. 2006, 1: 571-577.","journal-title":"Microbe"},{"key":"382_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/thx.2009.114512","volume":"65","author":"M Kolpen","year":"2010","unstructured":"Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van Gennip M, Ciofu O, Mandsberg L, Kharazmi A, D\u00f6ring G, Givskov M, H\u00f8iby N, Jensen P\u00d8: Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax. 2010, 65: 57-62. 10.1136\/thx.2009.114512.","journal-title":"Thorax"},{"key":"382_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0022-3476(84)80375-3","volume":"105","author":"J Levy","year":"1984","unstructured":"Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B: Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr. 1984, 105: 117-124. 10.1016\/S0022-3476(84)80375-3.","journal-title":"J Pediatr"},{"key":"382_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJM199901073400104","volume":"340","author":"BW Ramsey","year":"1999","unstructured":"Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999, 340: 23-30. 10.1056\/NEJM199901073400104.","journal-title":"N Engl J Med"},{"key":"382_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","volume":"167","author":"RL Gibson","year":"2003","unstructured":"Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B, Cystic Fibrosis Therapeutics Development Network Study Group: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003, 167: 841-849. 10.1164\/rccm.200208-855OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"382_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1378\/chest.122.1.219","volume":"122","author":"DE Geller","year":"2002","unstructured":"Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002, 122: 219-226. 10.1378\/chest.122.1.219.","journal-title":"Chest"},{"key":"382_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/jac\/dki461","volume":"57","author":"F Ratjen","year":"2006","unstructured":"Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H: Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006, 57: 306-311. 10.1093\/jac\/dki461.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"382_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jac\/12.suppl_A.313","volume":"12","author":"H Permin","year":"1983","unstructured":"Permin H, Koch C, H\u00f8iby N, Christensen HO, M\u00f8ller AF, M\u00f8ller S: Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother. 1983, 12 (Suppl A): 313-323.","journal-title":"J Antimicrob Chemother"},{"key":"382_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ppul.10336","volume":"36","author":"PM Farrell","year":"2003","unstructured":"Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makholm LM, Rock MJ, Splaingard ML: Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol. 2003, 36: 230-240. 10.1002\/ppul.10336.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/ppul.10135","volume":"34","author":"C Koch","year":"2002","unstructured":"Koch C: Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol. 2002, 34: 232-236. 10.1002\/ppul.10135.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2958.2008.06152.x","volume":"68","author":"SJ Pamp","year":"2008","unstructured":"Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T: Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol. 2008, 68: 223-240. 10.1111\/j.1365-2958.2008.06152.x.","journal-title":"Mol Microbiol"},{"key":"382_CR24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/jac\/19.6.831","volume":"19","author":"T Jensen","year":"1987","unstructured":"Jensen T, Pedersen SS, Garne S, Heilmann C, H\u00f8iby N, Koch C: Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987, 19: 831-838. 10.1093\/jac\/19.6.831.","journal-title":"J Antimicrob Chemother"},{"key":"382_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","volume":"338","author":"NH Valerius","year":"1991","unstructured":"Valerius NH, Koch C, H\u00f8iby N: Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991, 338: 725-726. 10.1016\/0140-6736(91)91446-2.","journal-title":"Lancet"},{"key":"382_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","volume":"16","author":"G D\u00f6ring","year":"2000","unstructured":"D\u00f6ring G, Conway SP, Heijerman HG, Hodson ME, H\u00f8iby N, Smyth A, Touw DJ: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000, 16: 749-767.","journal-title":"Eur Respir J"},{"key":"382_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","volume":"3","author":"G D\u00f6ring","year":"2004","unstructured":"D\u00f6ring G, H\u00f8iby N: Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004, 3: 67-91.","journal-title":"J Cyst Fibros"},{"key":"382_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","volume":"8","author":"H Heijerman","year":"2009","unstructured":"Heijerman H, Westerman E, Conway S, Touw D, D\u00f6ring G, Consensus Working Group: Inhaled medication and inhalation devices for lung diseases in patients with cystic fibrosis: a European consensus. J Cystic Fibros. 2009, 8: 295-315. 10.1016\/j.jcf.2009.04.005.","journal-title":"J Cystic Fibros"},{"key":"382_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4187\/aarc0537","volume":"54","author":"DE Geller","year":"2009","unstructured":"Geller DE: Aerosol antibiotics in cystic fibrosis. Respir Care. 2009, 54: 658-669. 10.4187\/aarc0537.","journal-title":"Respir Care"},{"key":"382_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ppul.20594","volume":"42","author":"DE Geller","year":"2007","unstructured":"Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C: Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007, 42: 307-313. 10.1002\/ppul.20594.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","volume":"6","author":"EM Westerman","year":"2007","unstructured":"Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, Heijerman HG: Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros. 2007, 6: 284-292. 10.1016\/j.jcf.2006.10.010.","journal-title":"J Cyst Fibros"},{"key":"382_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jcf.2010.08.012","volume":"9","author":"AJ Duff","year":"2010","unstructured":"Duff AJ, Latchford GJ: Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it. J Cyst Fibros. 2010, 9: 455-456. 10.1016\/j.jcf.2010.08.012.","journal-title":"J Cyst Fibros"},{"key":"382_CR33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ppul.21176","volume":"45","author":"TL Noah","year":"2010","unstructured":"Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, Henry MM, Leigh MW: Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol. 2010, 45: 281-290.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1378\/chest.08-1421","volume":"135","author":"GZ Retsch-Bogart","year":"2009","unstructured":"Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ: Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest. 2009, 135: 1223-1232. 10.1378\/chest.08-1421.","journal-title":"Chest"},{"key":"382_CR35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","volume":"178","author":"KS McCoy","year":"2008","unstructured":"McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB: Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008, 178: 921-928. 10.1164\/rccm.200712-1804OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"382_CR36","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/ppul.21301","volume":"45","author":"CM Oermann","year":"2010","unstructured":"Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ: An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010, 45: 1121-1134. 10.1002\/ppul.21301.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1569-1993(03)00024-9","volume":"2","author":"U Baumann","year":"2003","unstructured":"Baumann U, Stocklossa C, Greiner W, von der Schulenburg JM, von der Hardt H: Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros. 2003, 2: 84-90. 10.1016\/S1569-1993(03)00024-9.","journal-title":"J Cyst Fibros"},{"key":"382_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jcf.2005.05.018","volume":"4","author":"N H\u00f8iby","year":"2005","unstructured":"H\u00f8iby N, Frederiksen B, Pressler T: Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005, 4: 49-54.","journal-title":"J Cyst Fibros"},{"key":"382_CR39","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1136\/thx.2009.126128","volume":"65","author":"GA Tramper-Stranders","year":"2010","unstructured":"Tramper-Stranders GA, Wolfs TF, van Haren Noman S, van Aalderen WM, Nagelkerke AF, Nuijsink M, Kimpen JL, van der Ent CK: Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax. 2010, 65: 915-920. 10.1136\/thx.2009.126128.","journal-title":"Thorax"},{"key":"382_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.prrv.2009.12.003","volume":"11","author":"AA Yousef","year":"2010","unstructured":"Yousef AA, Jaffe A: The role of azithromycin in patients with cystic fibrosis. Paediatr Respir Rev. 2010, 11: 108-114. 10.1016\/j.prrv.2009.12.003.","journal-title":"Paediatr Respir Rev"},{"key":"382_CR41","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jama.2010.563","volume":"303","author":"L Saiman","year":"2010","unstructured":"Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, AZ0004 Azithromycin Study Group: Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010, 303: 1707-1715. 10.1001\/jama.2010.563.","journal-title":"JAMA"},{"key":"382_CR42","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","volume":"30","author":"M Treggiari","year":"2009","unstructured":"Treggiari M, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group: Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials. 2009, 30: 256-268. 10.1016\/j.cct.2009.01.003.","journal-title":"Contemp Clin Trials"},{"key":"382_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1569-1993(10)60210-X","volume":"9","author":"M Treggiari","year":"2010","unstructured":"Treggiari M, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kronmal R, Ramsey B, Accurso F, EPIC Investigators: Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis [Abstract]. J Cyst Fibros. 2010, 9: 54-10.1016\/S1569-1993(10)60210-X.","journal-title":"J Cyst Fibros"},{"key":"382_CR44","volume-title":"Scandinavian Cystic Fibosis Study Group: Prevention of chronic P. aeruginosa infection by antibiotic treatment of intermittent colonization in patients with cystic fibrosis: nebulized colistin + oral ciprofloxacin and azithromycin compared with colistin +","author":"N H\u00f8iby","year":"2009","unstructured":"H\u00f8iby N, Hansen CR, group: Scandinavian Cystic Fibosis Study Group: Prevention of chronic P. aeruginosa infection by antibiotic treatment of intermittent colonization in patients with cystic fibrosis: nebulized colistin + oral ciprofloxacin and azithromycin compared with colistin + oral ciprofloxacin. 2009, Copenhagen: Danish Cystic Fibrosis Center, Rigshospitalet Denmark"},{"key":"382_CR45","first-page":"302","volume":"45","author":"BC Trapnell","year":"2010","unstructured":"Trapnell BC, Rolfe M, McColley S, Montgomery AB, Moorehead L, Geller D: Fosfomycin\/tobramycin for inhalation (FTI): efficacy results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa [Abstract]. Pediatr Pulmonol. 2010, 45: 302.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR46","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ijantimicag.2009.12.011","volume":"35","author":"N H\u00f8iby","year":"2010","unstructured":"H\u00f8iby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O: Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010, 35: 322-332.","journal-title":"Int J Antimicrob Agents"},{"key":"382_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1569-1993(10)60158-0","volume":"9","author":"H Wang","year":"2010","unstructured":"Wang H, Wu H, Song Z, H\u00f8iby N: Ciprofloxacin shows concentration-dependent killing of P. aeruginosa biofilm in vitro [Abstract]. J Cyst Fibros. 2010, 9: 41-10.1016\/S1569-1993(10)60158-0.","journal-title":"J Cyst Fibros"},{"issue":"suppl. 33","key":"382_CR48","first-page":"314","volume":"45","author":"H Wang","year":"2010","unstructured":"Wang H, Wu H, Song Z, H\u00f8iby N: Colistin shows concentration-dependent killing of Pseudomonas aeruginosa biofilm in vitro [Abstract]. Pediatr Pulmonol. 2010, 45 (suppl. 33): 314.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR49","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1086\/656788","volume":"202","author":"G Herrmann","year":"2010","unstructured":"Herrmann G, Yang L, Wu H, Song Z, Wang H, H\u00f8iby N, Ulrich M, Molin S, Riethm\u00fcller J, D\u00f6ring G: Colistin-tobramycin combinations are superior to monotherapy concerning killing of biofilm Pseudomonas aeruginosa. J Infect Dis. 2010, 202: 1585-1592. 10.1086\/656788.","journal-title":"J Infect Dis"},{"key":"382_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1128\/JB.00720-06","volume":"189","author":"J Haagensen","year":"2007","unstructured":"Haagensen J, Klausen M, Ernst RK, Miller SI, Folkesson A, Tolker-Nielsen T, Molin S: Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol. 2007, 189: 28-37. 10.1128\/JB.00720-06.","journal-title":"J Bacteriol"},{"key":"382_CR51","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/08035250600752466","volume":"95","author":"B Frederiksen","year":"2006","unstructured":"Frederiksen B, Pressler T, Hansen A, Koch C, H\u00f8iby N: Effect of aerosolised rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr. 2006, 95: 1070-1074. 10.1080\/08035250600752466.","journal-title":"Acta Paediatr"},{"key":"382_CR52","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ppul.21193","volume":"45","author":"AR Smyth","year":"2010","unstructured":"Smyth AR, Cifelli PM, Ortori CA, Righetti K, Lewis S, Erskine P, Holland ED, Givskov M, Williams P, C\u00e1mara M, Barrett DA, Knox A: Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis: a pilot randomized controlled trial. Pediatr Pulmonol. 2010, 45: 356-362.","journal-title":"Pediatr Pulmonol"},{"key":"382_CR53","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2217\/fmb.09.38","volume":"4","author":"T Tolker-Nielsen","year":"2009","unstructured":"Tolker-Nielsen T, H\u00f8iby N: Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy. Future Microbiol. 2009, 4: 645-647. 10.2217\/fmb.09.38.","journal-title":"Future Microbiol"},{"key":"382_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jcf.2007.02.001","volume":"6","author":"G D\u00f6ring","year":"2007","unstructured":"D\u00f6ring G, Elborn JS, Johannesson M, de Jonge H, Griese M, Smyth A, Heijerman H, Consensus Study Group: Clinical trials in cystic fibrosis. J Cyst Fibros. 2007, 6: 85-99.","journal-title":"J Cyst Fibros"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-9-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-9-32\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-9-32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T06:51:39Z","timestamp":1637477499000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-9-32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,4]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-9-32","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,4]]},"article-number":"32"}}